Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-08-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
第六届监事会第六次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth meeting of the sixth supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. It focuses on the approval of a simplified procedure for a private placement of shares to specific investors in 2023, including the issuance plan, pricing, number of shares, use of proceeds, and related compliance matters. The document includes voting results and references to related detailed reports published elsewhere. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of capital raising plans and related board resolutions. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2023-08-11 Chinese
关于向特定对象发行证券预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (617 characters) regarding a 2023 plan for a simplified procedure to issue shares to specific targets by Harbin Yuheng Pharmaceutical Co., Ltd. It mentions board and supervisory meetings approving the plan and disclosure on the official information website. It explicitly states that the plan is subject to regulatory approval and contains a risk warning. There are no financial statements or detailed financial data, only a notice of a capital raising plan. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it contains substantive information about the capital issuance plan itself, not just a notice of report availability.
2023-08-11 Chinese
第六届董事会第七次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the sixth board of directors of Harbin Yuheng Pharmaceutical Co., Ltd. It includes approval of a simplified procedure for issuing shares to specific investors, details on the issuance plan, pricing, quantity, lock-up period, use of proceeds, and related reports. The document references legal and regulatory compliance, voting results, and independent directors' opinions. It is not a full financial report but rather a formal announcement of board decisions related to capital raising and share issuance. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update (CAP) category. The document length and detail confirm it is not a brief announcement or a simple report publication notice, but a substantive update on financing activities.
2023-08-11 Chinese
2023年度以简易程序向特定对象发行股票募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the feasibility analysis of the use of funds raised through a simplified procedure private placement of shares in 2023. It includes extensive information on the planned use of the raised funds, detailed investment projects (mainly drug R&D projects), project background, necessity, feasibility, market prospects, and investment budgets for multiple drug development projects. The document is lengthy (15,000 characters) and contains substantive financial and operational data related to capital raising and fund usage. It is not a simple announcement or a brief summary but a comprehensive report on capital raising and fund utilization. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes, specifically the issuance of shares to raise funds and the detailed use of those funds.
2023-08-11 Chinese
关于无需编制前次募集资金使用情况报告的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Harbin Yuheng Pharmaceutical Co., Ltd. stating that there is no need to prepare a report on the use of previously raised funds due to the time elapsed since the last fundraising exceeding five accounting years. It references regulatory guidelines from the China Securities Regulatory Commission and clarifies that no previous fundraising activities have occurred since the IPO. The document is brief (659 characters) and serves as a formal notice rather than a detailed financial report or audit. It does not contain financial statements or substantive financial data, nor does it present management discussion or voting results. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-11 Chinese
2023年度以简易程序向特定对象发行股票预案
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and announcement regarding a company's issuance of new shares to specific investors using a simplified procedure. It includes extensive information about the background, purpose, authorization, pricing, number of shares, use of proceeds, and regulatory approvals required. The document references Chinese securities laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is a comprehensive disclosure about a capital raising event through a private placement of shares, including financial and strategic rationale, but it is not a financial report, earnings release, or management discussion. It is not a proxy statement or voting results announcement. The document is lengthy (15,000 characters) and contains substantive content about the capital raising plan itself, not just an announcement of a report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-08-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.